Author | Edward B. Silberstein, MA, MD


An Alpha Edge?

April 17, 2012

One would hope that survival data from at least one more phase III or phase IV clinical trial will convincingly show a prolongation of survival due to treatment with Alpharadin. This will not be inexpensive therapy.

Painful Osteoblastic Metastases: The Role of Nuclear Medicine

February 01, 2001

Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not